S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:MGNX

MacroGenics Stock Forecast, Price & News

$26.01
+1.93 (+8.01 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.53
Now: $26.01
$26.16
50-Day Range
$18.99
MA: $21.72
$25.01
52-Week Range
$4.04
Now: $26.01
$32.18
Volume1.37 million shs
Average Volume793,611 shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.4
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. MacroGenics, Inc. has strategic collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was founded in 2000 and is headquartered in Rockville, Maryland.
MacroGenics logo

Headlines

MacroGenics: A Look At The DART Platform - Seeking Alpha
February 8, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172
Employees384
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.19 million
Book Value$4.71 per share

Profitability

Net Income$-151,810,000.00
Net Margins-204.31%

Miscellaneous

Market Cap$1.46 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

589th out of 1,969 stocks

Pharmaceutical Preparations Industry

274th out of 771 stocks

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$26.01
+1.93 (+8.01 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

Is MacroGenics a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 sell ratings, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MacroGenics stock.
View analyst ratings for MacroGenics
or view top-rated stocks.

What stocks does MarketBeat like better than MacroGenics?

Wall Street analysts have given MacroGenics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MacroGenics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for MacroGenics
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Wednesday, November, 4th. The biopharmaceutical company reported ($0.66) EPS for the quarter, beating the Zacks' consensus estimate of ($0.92) by $0.26. The biopharmaceutical company had revenue of $18.25 million for the quarter, compared to analysts' expectations of $10.28 million. MacroGenics had a negative net margin of 204.31% and a negative trailing twelve-month return on equity of 65.84%.
View MacroGenics' earnings history
.

How has MacroGenics' stock price been impacted by COVID-19 (Coronavirus)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MGNX shares have increased by 300.8% and is now trading at $26.01.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MGNX?

11 brokers have issued 1-year price objectives for MacroGenics' stock. Their forecasts range from $14.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $30.70 in the next year. This suggests a possible upside of 18.0% from the stock's current price.
View analysts' price targets for MacroGenics
or view top-rated stocks among Wall Street analysts.

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 69, Pay $905.44k)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 54, Pay $533.25k)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 67, Pay $575.14k)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 48, Pay $531.38k)
  • Anna Krassowska Ph.D., VP of Investor Relations & Corp. Communications
  • Mr. Jeffrey Stuart Peters, VP & Gen. Counsel (Age 50)
  • Dr. Thomas M. Spitznagel, Sr. VP of BioPharmaceutical Devel. & Manufacturing (Age 54)
  • Dr. Stephen L. Eck, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 66)
  • Ms. Lynn Cilinski, VP, Controller & Treasurer (Age 63)

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics CEO Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among MacroGenics' employees.

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.08%), Dimensional Fund Advisors LP (2.18%), Nuveen Asset Management LLC (1.58%), Hood River Capital Management LLC (1.23%), Candriam Luxembourg S.C.A. (1.20%) and Northern Trust Corp (1.16%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, Kenneth Galbraith and Thomas Spitznagel.
View institutional ownership trends for MacroGenics
.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Dimensional Fund Advisors LP, Pinnacle Associates Ltd., Russell Investments Group Ltd., Victory Capital Management Inc., Rhenman & Partners Asset Management AB, Barclays PLC, and Virtus ETF Advisers LLC. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, Kenneth Galbraith, and Thomas Spitznagel.
View insider buying and selling activity for MacroGenics
or view top insider-selling stocks.

Which major investors are buying MacroGenics stock?

MGNX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Baker BROS. Advisors LP, Tudor Investment Corp Et Al, Panagora Asset Management Inc., Candriam Luxembourg S.C.A., JPMorgan Chase & Co., First Trust Advisors LP, and Wells Fargo & Company MN.
View insider buying and selling activity for MacroGenics
or or view top insider-buying stocks.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $26.01.

How much money does MacroGenics make?

MacroGenics has a market capitalization of $1.46 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis.

How many employees does MacroGenics have?

MacroGenics employs 384 workers across the globe.

What is MacroGenics' official website?

The official website for MacroGenics is www.macrogenics.com.

Where are MacroGenics' headquarters?

MacroGenics is headquartered at 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.